Race Oncology Ltd Total Liabilities
Race Oncology Ltd total liabilities. Based on the latest financial reports, Race Oncology Ltd (RAC) has total liabilities worth AU$1.64 Million AUD (≈ $1.16 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check RAC financial resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Race Oncology Ltd (2011–2026)
Total liabilities of Race Oncology Ltd from 2011 to 2026. This chart illustrates how Race Oncology Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore RAC long-term investment intensity to see how much of total assets are deployed in long-term investments.
Race Oncology Ltd Competitors by Total Liabilities
The table below lists competitors of Race Oncology Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Ace Pillar Co Ltd
TW:8374
|
Taiwan | NT$2.83 Billion |
|
Condor Energies Inc.
TO:CDR
|
Canada | CA$86.14 Million |
|
Henan BCCY Environmental Energy Co. Ltd
SHE:300614
|
China | CN¥896.06 Million |
|
Vizsla Royalties Corp.
V:VROY
|
Canada | CA$499.70K |
|
BAJEL PROJECTS LTD
NSE:BAJEL
|
India | Rs-7.48 Billion |
|
P.C.B Tec
TA:PCBT
|
Israel | ILA76.95 Million |
|
Blue Bird Tbk PT
JK:BIRD
|
Indonesia | Rp3.39 Trillion |
|
Omaxe Limited
NSE:OMAXE
|
India | Rs8.93 Billion |
Liability Composition Analysis (2011–2026)
This chart breaks down Race Oncology Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Race Oncology Ltd total assets.
Liquidity & Leverage Metrics
Race Oncology Ltd Total Liabilities Ratios Explained
Race Oncology Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 21.43 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.05 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.04 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Race Oncology Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Race Oncology Ltd (2011–2026)
The table below shows the annual total liabilities of Race Oncology Ltd from 2011 to 2026.
| Year | Total Liabilities | Change |
|---|---|---|
| 2026-06-30 | AU$1.64 Million ≈ $1.16 Million |
+11.14% |
| 2025-06-30 | AU$1.48 Million ≈ $1.05 Million |
-22.85% |
| 2024-06-30 | AU$1.92 Million ≈ $1.36 Million |
+66.39% |
| 2023-06-30 | AU$1.15 Million ≈ $814.97K |
-18.74% |
| 2022-06-30 | AU$1.42 Million ≈ $1.00 Million |
+170.95% |
| 2021-06-30 | AU$523.11K ≈ $370.13K |
+114.70% |
| 2020-06-30 | AU$243.65K ≈ $172.40K |
+26.82% |
| 2019-06-30 | AU$192.12K ≈ $135.94K |
-37.97% |
| 2018-06-30 | AU$309.71K ≈ $219.14K |
-14.82% |
| 2017-06-30 | AU$363.57K ≈ $257.25K |
-7.16% |
| 2016-06-30 | AU$391.62K ≈ $277.10K |
+229.70% |
| 2015-06-30 | AU$118.78K ≈ $84.04K |
-10.05% |
| 2014-06-30 | AU$132.05K ≈ $93.43K |
-99.93% |
| 2013-12-31 | AU$191.01 Million ≈ $135.15 Million |
+1611781.86% |
| 2013-06-30 | AU$11.85K ≈ $8.38K |
-100.00% |
| 2012-12-31 | AU$264.98 Million ≈ $187.49 Million |
-20.07% |
| 2012-06-30 | AU$331.51 Million ≈ $234.56 Million |
+21.34% |
| 2011-06-30 | AU$273.20 Million ≈ $193.31 Million |
-- |
About Race Oncology Ltd
Racura Oncology Ltd operates as a clinical-stage biopharmaceutical company in Australia. It develops RC220, a formulation of (E,E)-bisantrene, which is in Phase III clinical trial for the treatment of acute myeloid leukemia; Phase Ia/b clinical trial for the treatment of epidermal growth factor receptor-mutated non-small cell lung cancer; and Phase Ia/b clinical trial for the treatment of solid t… Read more